TLSI vs. SILK, CATX, ATRI, KIDS, PLSE, EMBC, FNA, SIBN, OFIX, and IRMD
Should you be buying TriSalus Life Sciences stock or one of its competitors? The main competitors of TriSalus Life Sciences include Silk Road Medical (SILK), Perspective Therapeutics (CATX), Atrion (ATRI), OrthoPediatrics (KIDS), Pulse Biosciences (PLSE), Embecta (EMBC), Paragon 28 (FNA), SI-BONE (SIBN), Orthofix Medical (OFIX), and Iradimed (IRMD). These companies are all part of the "surgical & medical instruments" industry.
Silk Road Medical (NASDAQ:SILK) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Silk Road Medical has higher revenue and earnings than TriSalus Life Sciences.
TriSalus Life Sciences has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -29.02%. Silk Road Medical's return on equity of 0.00% beat TriSalus Life Sciences' return on equity.
In the previous week, Silk Road Medical had 7 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 13 mentions for Silk Road Medical and 6 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.66 beat Silk Road Medical's score of 0.64 indicating that Silk Road Medical is being referred to more favorably in the media.
Silk Road Medical has a beta of 1.43, indicating that its share price is 43% more volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
Silk Road Medical received 87 more outperform votes than TriSalus Life Sciences when rated by MarketBeat users. However, 100.00% of users gave TriSalus Life Sciences an outperform vote while only 50.56% of users gave Silk Road Medical an outperform vote.
Silk Road Medical presently has a consensus target price of $20.10, indicating a potential downside of 7.54%. TriSalus Life Sciences has a consensus target price of $13.33, indicating a potential upside of 86.22%. Given Silk Road Medical's stronger consensus rating and higher probable upside, analysts clearly believe TriSalus Life Sciences is more favorable than Silk Road Medical.
2.6% of TriSalus Life Sciences shares are held by institutional investors. 3.9% of Silk Road Medical shares are held by insiders. Comparatively, 76.2% of TriSalus Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Silk Road Medical and TriSalus Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.
Get TriSalus Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for TLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TriSalus Life Sciences Competitors List
Related Companies and Tools
